Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer

Allan Lipton; Harold Harvey; R. J. Santen; A. Boucher; D. White; A. Bernath; R. Dixon; G. Richards; A. Shafik

Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer

Allan Lipton, Harold Harvey, R. J. Santen, A. Boucher, D. White, A. Bernath, R. Dixon, G. Richards, A. Shafik

Research output: Contribution to journal › Article › peer-review

Abstract

We compared antiestrogen therapy (tamoxifen) with an estrogen suppression regimen (aminoglutethimide-hydrocortisone) in postmenopausal women with metastatic breast carcinoma. Fifteen of 39 patients (38%) who received tamoxifen experienced an objective tumor regression (3 complete, 12 partial remissions), whereas 13 of 36 women (36%) receiving aminoglutethimide responded (one complete remission, 12 partial remissions). The median duration of response was similar. The site of tumor involvement appears to be important in choosing between these hormonal treatments. Aminoglutethimide appears to offer a greater chance of response in patients with bone involvement.

Original language	English (US)
Pages (from-to)	3434s-3436s
Journal	Cancer Research
Volume	42
Issue number	8 Suppl.
State	Published - 1982

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{940c68c0a4684fa99f2b0f243c4aaab7,

title = "Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer",

abstract = "We compared antiestrogen therapy (tamoxifen) with an estrogen suppression regimen (aminoglutethimide-hydrocortisone) in postmenopausal women with metastatic breast carcinoma. Fifteen of 39 patients (38%) who received tamoxifen experienced an objective tumor regression (3 complete, 12 partial remissions), whereas 13 of 36 women (36%) receiving aminoglutethimide responded (one complete remission, 12 partial remissions). The median duration of response was similar. The site of tumor involvement appears to be important in choosing between these hormonal treatments. Aminoglutethimide appears to offer a greater chance of response in patients with bone involvement.",

author = "Allan Lipton and Harold Harvey and Santen, {R. J.} and A. Boucher and D. White and A. Bernath and R. Dixon and G. Richards and A. Shafik",

year = "1982",

language = "English (US)",

volume = "42",

pages = "3434s--3436s",

journal = "Cancer Research",

issn = "0008-5472",

number = "8 Suppl.",

}

TY - JOUR

T1 - Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer

AU - Lipton, Allan

AU - Harvey, Harold

AU - Santen, R. J.

AU - Boucher, A.

AU - White, D.

AU - Bernath, A.

AU - Dixon, R.

AU - Richards, G.

AU - Shafik, A.

PY - 1982

Y1 - 1982

N2 - We compared antiestrogen therapy (tamoxifen) with an estrogen suppression regimen (aminoglutethimide-hydrocortisone) in postmenopausal women with metastatic breast carcinoma. Fifteen of 39 patients (38%) who received tamoxifen experienced an objective tumor regression (3 complete, 12 partial remissions), whereas 13 of 36 women (36%) receiving aminoglutethimide responded (one complete remission, 12 partial remissions). The median duration of response was similar. The site of tumor involvement appears to be important in choosing between these hormonal treatments. Aminoglutethimide appears to offer a greater chance of response in patients with bone involvement.

AB - We compared antiestrogen therapy (tamoxifen) with an estrogen suppression regimen (aminoglutethimide-hydrocortisone) in postmenopausal women with metastatic breast carcinoma. Fifteen of 39 patients (38%) who received tamoxifen experienced an objective tumor regression (3 complete, 12 partial remissions), whereas 13 of 36 women (36%) receiving aminoglutethimide responded (one complete remission, 12 partial remissions). The median duration of response was similar. The site of tumor involvement appears to be important in choosing between these hormonal treatments. Aminoglutethimide appears to offer a greater chance of response in patients with bone involvement.

UR - http://www.scopus.com/inward/record.url?scp=0020328459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020328459&partnerID=8YFLogxK

M3 - Article

C2 - 7044526

AN - SCOPUS:0020328459

SN - 0008-5472

VL - 42

SP - 3434s-3436s

JO - Cancer Research

JF - Cancer Research

IS - 8 Suppl.

ER -

Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this